Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Liabilities and Shareholders Equity (2016 - 2025)

Ascendis Pharma A (ASND) has disclosed Liabilities and Shareholders Equity for 10 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 20.3% to $1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 billion through Dec 2025, up 6.11% year-over-year, with the annual reading at $1.5 billion for FY2025, 20.3% up from the prior year.
  • Liabilities and Shareholders Equity hit $1.5 billion in Q4 2025 for Ascendis Pharma A, up from $1.3 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.5 billion in Q4 2025 to a low of $888.3 million in Q4 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2021.
  • Biggest five-year swings in Liabilities and Shareholders Equity: fell 20.1% in 2023 and later soared 41.89% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $1.2 billion in 2021, then fell by 10.42% to $1.1 billion in 2022, then dropped by 20.1% to $888.3 million in 2023, then skyrocketed by 41.89% to $1.3 billion in 2024, then rose by 20.3% to $1.5 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ASND at $1.5 billion in Q4 2025, $1.3 billion in Q4 2024, and $888.3 million in Q4 2023.